Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024 17:38 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted...
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
May 10, 2024 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing’s Syndrome Will be Presented at ENDO...
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
May 08, 2024 07:00 ET
|
Kamada Ltd.
Revenues for First Quarter of 2024 were $37.7 Million, Representing a 23% Increase Year-over-YearFirst Quarter 2024 Adjusted EBITDA of $7.5 Million, Representing a 96% Increase Year-over-YearMomentum...
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
May 07, 2024 07:00 ET
|
Theriva Biologics, Inc.
- Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the...
OptimizeRx to Participate in Upcoming Investor Conferences
May 06, 2024 16:30 ET
|
OptimizeRx Corporation
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and...
Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
April 30, 2024 16:05 ET
|
Predictive Oncology Inc.
PITTSBURGH, April 30, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a...
Fujifilm and Predictive Oncology Announce Collaboration to Reduce Protein Interference in Bacterial Endotoxin Detection Testing of Biopharmaceuticals
April 25, 2024 09:17 ET
|
FUJIFILM Holdings America Corporation
RICHMOND, VA, and PITTSBURGH, April 25, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Wako Chemicals U.S.A. Corporation (Fujifilm), a supplier of high purity chemicals and reagents, and Predictive Oncology...
Opthea to Present at the OIS Retina Innovation Summit at ARVO
April 25, 2024 09:00 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...